Standard BioTools Receives $30 Million from Illumina and Sells Mass Cytometry Business to Multiplex Bio

Illumina Agreement Eliminates Future Payment Obligations

Standard BioTools and Illumina executed a Termination, Waiver and Release Agreement on July 24, 2026, fundamentally restructuring their prior commercial relationship. Under the agreement, Standard BioTools waived its entitlement to a 2026 earnout payment based on net revenue from SomaScan assay services and SOMAmer-based array and sequencing kits that Illumina had agreed to pay under a June 22, 2025 stock purchase agreement. In exchange for this waiver, Illumina transferred approximately $30 million in cash to Standard BioTools.

Beyond the earnout waiver, Standard BioTools also agreed to terminate the Royalty and License Agreements that had been established on January 30, 2026. These agreements had granted the company specified royalty streams on net revenues from SOMAmer-based next-generation sequencing library preparation kits and Single SOMAmers, as well as a license to develop and commercialize Single SOMAmer reagents for singleplex affinity assays. The complete termination of these agreements eliminates future royalty income but provides immediate liquidity to the company during a period of significant corporate transition.

Mass Cytometry Business Divested to Multiplex Bio

On July 28, 2026, Standard BioTools entered into a Share and Asset Purchase Agreement with Multiplex Bio Inc. to sell its mass cytometry business. The transaction establishes a purchase price of $5 million on a cash-free and debt-free basis, subject to customary adjustments. Notably, the purchase price will be paid entirely through the issuance of a promissory note from Multiplex Bio to Standard BioTools, bearing interest at 6% per annum and maturing five years from closing. Standard BioTools will receive no cash proceeds at the closing, instead holding the debt obligation as an asset.

The purchase agreement includes a contingent earnout provision under which Standard BioTools may receive an additional $5 million if Multiplex Bio successfully completes a qualifying sale transaction generating consideration exceeding a specified threshold within ten years of closing. The agreement also requires Multiplex Bio to attempt to secure a senior secured working capital loan facility following closing. If Multiplex Bio is unable to obtain such financing despite reasonable efforts, Standard BioTools is obligated to provide a working capital loan of up to $10 million at closing. Post-closing, the company will provide transition services to Multiplex Bio to support its operation of the mass cytometry business.

Stockholder Approval and Regulatory Conditions Required

Consummation of both transactions is contingent upon multiple conditions that investors should monitor closely. The closing of the Multiplex Bio purchase agreement requires approval from Standard BioTools stockholders, a requirement that introduces execution risk and timing uncertainty. Additionally, the completion of Standard BioTools' pending merger with Treeline Biosciences must be consummated before the mass cytometry sale can close, creating interdependency between two significant corporate actions.

The purchase agreement permits Standard BioTools' board of directors to solicit alternative proposals to acquire the mass cytometry business and retains customary fiduciary-out rights. If an unsolicited competing proposal emerges that the board determines to be more favorable to stockholders, the board may recommend acceptance of that alternative, subject to Multiplex Bio's notice and matching rights. The current agreement is expected to remain in effect until June 30, 2027, with automatic extensions possible under specified circumstances.

Termination Fee Structure and Deal Economics

The purchase agreement includes financial provisions that protect both parties and reflect customary deal protections. Standard BioTools will be required to pay Multiplex Bio a termination fee of $1 million in cash if the transaction is terminated under specified circumstances. Additionally, the company must reimburse Multiplex Bio's reasonable out-of-pocket expenses in incremental amounts if closing does not occur by specified dates: up to $125,000 if the transaction does not close by December 31, 2026, and an additional $125,000 if it does not close by March 31, 2027.

These termination fee provisions are designed to compensate Multiplex Bio for transaction costs and lost opportunity. However, any expense reimbursements made are credited against the $1 million termination fee, reducing the maximum total financial obligation Standard BioTools could face. The staggered reimbursement schedule creates intermediate milestones that both parties will be monitoring as they work toward closing the transaction.

Timing and Expected Milestones for Closing

The purchase agreement establishes June 30, 2027 as the target closing date, providing approximately one year from the announcement for the parties to satisfy closing conditions and obtain necessary approvals. The filing indicates that the agreement contemplates automatic three-month extensions under certain specified circumstances, extending the outside date potentially to September 30, 2027. This extended timeline accommodates both stockholder approval processes and the required closing of the Treeline Biosciences merger.

Standard BioTools will need to conduct stockholder outreach and secure approval before the mass cytometry transaction can close. The interlock with the Treeline merger creates a sequential approval requirement that could extend timelines if either transaction encounters delays. The company and Multiplex Bio are expected to enter into ancillary agreements at closing, including a transition services agreement that will establish the scope and duration of post-closing support Standard BioTools will provide for mass cytometry operations.

Strategic Implications of Portfolio Restructuring

These transactions represent a deliberate portfolio restructuring for Standard BioTools, effectively narrowing the company's product focus and operational scope. By divesting the mass cytometry business to Multiplex Bio, Standard BioTools is exiting a capital-intensive product line while maintaining a potential earnings participation through the contingent earnout provision. The sale proceeds will be structured as deferred consideration through a promissory note, providing Multiplex Bio with time to integrate and grow the business.

Simultaneously, the termination of Illumina payment obligations eliminates both potential future earnings and the complexity of royalty accounting and revenue recognition. The $30 million cash receipt from Illumina provides immediate financial resources that may support Standard BioTools' broader strategic objectives, including the integration with Treeline Biosciences. For investors, these transactions suggest management believes its core business portfolio will be better positioned for growth and profitability as part of the combined Treeline entity.

Forward-Looking Execution Risks and Uncertainties

While both transactions have been structured with customary protections, several execution risks remain that investors should monitor. The requirement for stockholder approval introduces uncertainty regarding whether shareholders will support the mass cytometry divestiture and the overall strategic direction. If shareholders withhold approval, Standard BioTools would be unable to complete the sale, potentially requiring management to pursue alternative paths for that business segment.

The interdependency with the Treeline Biosciences merger creates timing complexity and introduces the possibility that delays in one transaction could cascade to the other. Additionally, if Multiplex Bio is unable to secure the required working capital financing and Standard BioTools must provide a loan of up to $10 million, that obligation could impact the combined company's liquidity and capital allocation in ways not yet fully specified in public disclosures. The contingent earnout payment, while potentially valuable, is dependent on Multiplex Bio's ability to execute a successful sale transaction within ten years, an outcome beyond Standard BioTools' direct control.

Investor Considerations Regarding Deal Structure

The deal structure warrants particular attention from Standard BioTools shareholders evaluating the transactions. The mass cytometry sale consideration consists entirely of a five-year promissory note rather than cash, creating credit risk and timing uncertainty regarding when value is realized. While the 6% interest rate provides some compensation for the time value of money and credit risk, investors should assess their comfort with receiving a substantial portion of deferred consideration in a non-cash form.

The potential $5 million earnout for the Multiplex Bio transaction introduces contingent value that depends on market conditions, Multiplex Bio's execution, and successful completion of a qualifying sale within the ten-year window. Investors should consider the probability of earnout realization when evaluating the overall transaction value. The $30 million payment from Illumina, by contrast, is immediate cash that enhances Standard BioTools' liquidity position and provides fungible resources for corporate purposes, though it comes at the cost of surrendering future royalty income that could have proven substantial if SOMAmer-based products performed strongly in the market.

Announcement Details and Timing

Standard BioTools announced both transactions through a press release issued on July 28, 2026, the same day the Multiplex Bio purchase agreement was executed. This announcement followed by four days the Illumina termination agreement dated July 24, 2026. The staggered timing suggests the two transactions may have been negotiated sequentially or in parallel but finalized on different dates. The company disclosed these matters via current report disclosures made pursuant to Securities and Exchange Commission rules, with the Illumina agreement characterized as a material definitive agreement under Item 1.01 and the press release furnishings under Item 7.01.

The filing notes that forward-looking statements within the announcement are subject to the Private Securities Litigation Reform Act of 1995. This language indicates that management has included projections or expectations regarding the timing of the mass cytometry divestiture, the Treeline merger, and other future developments. Investors should recognize that actual outcomes may differ materially from stated expectations, particularly given the multiple closing conditions and regulatory approvals required for both transactions to complete successfully.